Class Action

Robitussin Cough Medicine with DXM

Class Action

Robitussin Cough Medicine with DXM


Case Names (Date)

Bell et al. v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC et al.
21-cv-9454, C.D. Cal.
(Dec. 2021)

Calchi et al. v GlaxoSmithKline Consumer Healthcare Holdings (US) LLC et al.
22-cv-1341, S.D.N.Y.
(Feb. 2022)

Muller et al. v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
22-cv-670, E.D. Mo.
(May 2022)

Papalia et al. v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
22-cv-2630, S.D.N.Y.
(March 2022)


Product/Service

Robitussin cough medicine with dextromethorphan hydrobromide (DXM)


Allegations

Falsely marketing medicine as “Non-Drowsy” when the active ingredient causes drowsiness


Status

Bell case: Voluntarily dismissed

Calchi case: Claims against Pfizer were dismissed; Motion for preliminary approval of a settlement agreement that would resolve claims against GSK filed

Muller case: Pending

Papalia case: Consolidated with the Calchi case



Class-Action Tracker

Abreva

Class Action

Abreva

Allegations: Misleadingly marketing Abreva cold sore treatments


The Latest

Filters